Canaccord Genuity set a $26.00 price target on Voyager Therapeutics (NASDAQ:VYGR) in a research report sent to investors on Wednesday, November 15th. The firm currently has a buy rating on the stock.
A number of other equities research analysts have also weighed in on VYGR. ValuEngine lowered shares of Voyager Therapeutics from a sell rating to a strong sell rating in a research note on Friday, July 28th. Stifel Nicolaus started coverage on shares of Voyager Therapeutics in a research note on Friday, July 28th. They set a buy rating and a $20.00 price objective on the stock. Cowen reissued a buy rating on shares of Voyager Therapeutics in a research note on Tuesday, August 8th. Zacks Investment Research lowered shares of Voyager Therapeutics from a hold rating to a sell rating in a research note on Friday, August 11th. Finally, Evercore ISI started coverage on shares of Voyager Therapeutics in a research note on Wednesday, August 16th. They set an outperform rating and a $12.00 price objective on the stock. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $26.33.
Voyager Therapeutics (NASDAQ:VYGR) traded down $0.61 during mid-day trading on Wednesday, hitting $13.83. 406,979 shares of the company’s stock were exchanged, compared to its average volume of 246,785. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $25.99.
In related news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00. Following the completion of the transaction, the insider now owns 17,157 shares in the company, valued at $171,570. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 38,430 shares of company stock valued at $562,890. 8.00% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Iguana Healthcare Management LLC purchased a new stake in shares of Voyager Therapeutics in the third quarter valued at $515,000. Point72 Asset Management L.P. purchased a new position in Voyager Therapeutics in the 3rd quarter worth about $2,695,000. Dimensional Fund Advisors LP increased its stake in Voyager Therapeutics by 7.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 105,914 shares of the company’s stock worth $2,181,000 after buying an additional 7,786 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Voyager Therapeutics by 71.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 49,788 shares of the company’s stock worth $1,026,000 after buying an additional 20,753 shares during the period. Finally, Mckinley Capital Management LLC Delaware purchased a new position in Voyager Therapeutics in the 3rd quarter worth about $1,412,000. 35.97% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Voyager Therapeutics (NASDAQ:VYGR) PT Set at $26.00 by Canaccord Genuity” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/voyager-therapeutics-inc-vygr-given-a-26-00-price-target-at-canaccord-genuity.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.